1. Zymeworks and BeiGene announce license and collaboration agreement for Zymeworks’ HER2-Targeted therapeutic candidates, ZW25 and ZW49, in Asia-Pacific and research and license agreement for Zymeworks’ Azymetric™ and EFECT™ platforms globally. www.businesswire.com/news/home/20181127005311/en/Zymeworks-BeiGene-Announce-License-Collaboration-Agreement-Zymeworks%E2%80%99
2. Generex Biotechnology expands medical device portfolio with acquisition of Olaregen Therapeutix Inc. www.businesswire.com/news/home/20181128005244/en/Generex-Biotechnology-Expands-Medical-Device-Portfolio-Acquisition
3. Oasmia Pharmaceutical AB announces new agreement with Baxter Oncology GmbH for global commercial manufacturing of Apealea®. https://oasmia.com/en/press-release/oasmia-pharmaceutical-ab-announces-new-agreement-baxter-oncology-gmbh-global-commercial-manufacturing-apealea/
4. Oasmia Pharmaceutical receives approval from European Commission for Apealea®(paclitaxel micellar) in the European Union. https://globenewswire.com/news-release/2018/11/22/1655521/0/en/Oasmia-Pharmaceutical-Receives-Approval-from-European-Commission-for-Apealea-paclitaxel-micellar-in-the-European-Union.html
5. Tetra Bio-Pharma bolsters intellectual property position and product pipeline. https://tetrabiopharma.com/investors/press-releases/press-release-details/2018/Tetra-Bio-Pharma-Bolsters-Intellectual-Property-Position-and-Product-Pipeline/default.aspx